Indeed, ITGAL, ITGAX, and the panel of these three genes (IIT) estimate the response of NSCLC to anti-PD1 therapy more efficiently than the panel of well-established ICB biomarkers, including PD-L1 (CD274), INFγ, CD8, and Merck18 (Figure 3C). Here, CD8A is linked to non-small cell lung carcinoma.